Opinion: ALDH2 deficiency and the genetics behind alcohol flushing deserves greater clinical attention

An opinion article published by Stat News, written by Brian Zhang, a medical student, argues that the alcohol-flushing response colloquially known as 'Asian glow' is underpinned by inherited variation in the ALDH2 gene and that its associated health risks are insufficiently explained to patients by clinicians.

ALDH2 encodes aldehyde dehydrogenase 2, the enzyme responsible for metabolising acetaldehyde — a toxic intermediate produced during ethanol metabolism. Individuals carrying the ALDH2*2 allele (rs671), which is present at high frequency in populations of East Asian ancestry, have reduced or absent enzyme activity. This leads to acetaldehyde accumulation after alcohol consumption, producing characteristic facial flushing, tachycardia, and nausea. Epidemiological studies have associated ALDH2*2 homozygosity and heterozygosity with elevated risk of oesophageal cancer in people who consume alcohol, a relationship that has been documented in published literature for several decades.

The article is explicitly an opinion piece and advocacy in framing rather than a primary research report. It does not present new data. Its relevance to Genetic Current readers lies in the underlying genetics: ALDH2 is a well-characterised pharmacogenomic and population-genetics example, and the broader question of how population-frequency variants with significant phenotypic consequences are communicated across clinical settings is relevant to genetic counsellors, GPs with genetics-aware patient populations, and educators.

For educators, the ALDH2*2 allele represents a textbook example of a founder-effect-associated variant with measurable health consequences — relevant to teaching population genetics, pharmacogenomics, and gene–environment interaction.